Sublingual vaccines based on wild-type recombinant allergens.
Sublingual immunotherapy (SLIT) represents a non invasive alternative to subcutaneous immunotherapy in order to treat type I allergies. Vaccines based on recombinant allergens expressed in a native (i.e. wild-type) configuration, formulated with ad hoc adjuvants designed to target Langerhans cells in the sublingual mucosa should allow to induce allergen-specific regulatory T cells. In this context, we have developed animal and human preclinical models to test the capacity of candidate vaccines to modulate selectively allergen-specific T helper lymphocyte polarization following sublingual vaccination.
Van Overtvelt
L
L
Stallergènes SA - 6, rue Alexis de Tocqueville - 92160 Antony, France.
Razafindratsita
A
A
St-Lu
N
N
Didierlaurent
A
A
Batard
Th
T
Lombardi
V
V
Martin
E
E
Moingeon
Ph
P
D000276:Adjuvants, Immunologic; D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage*; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000485:Allergens; D011994:Recombinant Proteins; D014612:Vaccines